| Name | Title | Contact Details |
|---|---|---|
Chris Caldwell |
Vice President, Global Sales Support | Profile |
Prashanth Urs |
Associate IT Product Director | Profile |
Charles Rapier |
Sr. Director IT, R&D Solutions | Profile |
Lincoln Bynum |
VP, Clinical R&D | Profile |
Dan Johnson |
Vice President, Executive Talent | Profile |
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.
Eyetech Pharmaceuticals, Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Chi Scientific is a Maynard, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PCI Pharma Services is a global leader in Contract Development and Manufacturing Organization (CDMO) services, offering integrated solutions for drug development, manufacturing, and packaging. The company focuses on innovation and patient-centric approaches, supporting pharmaceutical and biopharmaceutical companies at various stages of drug development and commercialization. With 30 Good Manufacturing Practice (GMP) facilities across seven countries, PCI employs over 4,300 people dedicated to delivering life-changing therapies. The company provides a comprehensive range of services, including drug development and manufacturing for various dosage forms, advanced drug delivery systems, and complex packaging solutions. PCI also manages storage, distribution, and logistics to support the pharmaceutical supply chain and offers clinical trial supply chain management. Committed to growth, PCI has made significant investments, including a $100 million expansion in New England to enhance its global capacity and capabilities.
Cultiv8 Hemp Solutions, Inc. specializes in the growth and harvest of industrial hemp. We manufacture biodegradable paper and plastic alternatives, as well as biofuel, protien, and biomass.